Christopher A. Eide

10.2k total citations · 2 hit papers
97 papers, 3.9k citations indexed

About

Christopher A. Eide is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Christopher A. Eide has authored 97 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Hematology, 59 papers in Genetics and 33 papers in Molecular Biology. Recurrent topics in Christopher A. Eide's work include Chronic Myeloid Leukemia Treatments (64 papers), Chronic Lymphocytic Leukemia Research (46 papers) and Acute Myeloid Leukemia Research (34 papers). Christopher A. Eide is often cited by papers focused on Chronic Myeloid Leukemia Treatments (64 papers), Chronic Lymphocytic Leukemia Research (46 papers) and Acute Myeloid Leukemia Research (34 papers). Christopher A. Eide collaborates with scholars based in United States, India and Brazil. Christopher A. Eide's co-authors include Brian Druker, Thomas O’Hare, Michael W. Deininger, Jeffrey Tyner, Theodore P. Braun, Anupriya Agarwal, Stephanie G. Willis, Marc Loriaux, Shannon K. McWeeney and Cristina E. Tognon and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Blood.

In The Last Decade

Christopher A. Eide

88 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CML

2013 356 citations Julia E. Maxson, Jason Gotlib et al. profile →
Response and Resistance to BCR-ABL1-Targeted Therapies

2020 308 citations Theodore P. Braun, Christopher A. Eide et al. profile →

Peers

Countries citing papers authored by Christopher A. Eide

Since Specialization

Citations

This map shows the geographic impact of Christopher A. Eide's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher A. Eide with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher A. Eide more than expected).

Fields of papers citing papers by Christopher A. Eide

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher A. Eide. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher A. Eide. The network helps show where Christopher A. Eide may publish in the future.

Co-authorship network of co-authors of Christopher A. Eide

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher A. Eide. A scholar is included among the top collaborators of Christopher A. Eide based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher A. Eide. Christopher A. Eide is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	DDX41-Mutated AML: A Case Report and Perspectives 2026 ·JCO Precision Oncology ·(unknown), Christopher A. Eide, Stephen E. Kurtz, Nicola Long, Kara Johnson, Cristina E. Tognon, Brian Druker, (unknown), (unknown)	0
2	Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminib 2025 ·Science Signaling ·Serena Muratcioğlu, Christopher A. Eide, (unknown), (unknown), (unknown), Wenqi Zuo, Jay T. Groves, Brian Druker, John Kuriyan	0
3	Influence of AML Differentiation State in Risk Stratification of Frontline Therapy with Hypomethylating Agents + Venetoclax in AML 2024 ·Blood ·Curtis A. Lachowiez, Joshua F. Zeidner, (unknown), D. Peters, (unknown), (unknown), Andy Kaempf, Fangyan Dai, Christopher A. Eide, Stephen E. Kurtz, Theodore P. Braun, Ronan Swords, Jennifer N. Saultz, Jeffrey Tyner, Daniel A. Pollyea	0
4	Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy 2023 ·Blood Cancer Discovery ·Christopher A. Eide, Stephen E. Kurtz, Andy Kaempf, Nicola Long, Sunil K. Joshi, Tamilla Nechiporuk, (unknown), (unknown), (unknown), Daniel Bottomly, Shannon K. McWeeney, Jessica Minnier, Curtis A. Lachowiez, Jennifer N. Saultz, Ronan Swords, Anupriya Agarwal, Bill H. Chang, Brian Druker, Jeffrey Tyner	12
5	Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia 2022 ·Blood Advances ·Stephen E. Kurtz, Christopher A. Eide, Andy Kaempf, Nicola Long, Daniel Bottomly, Olga Nikolova, Brian Druker, Shannon K. McWeeney, Bill H. Chang, Jeffrey Tyner, Anupriya Agarwal	6
6	Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations 2021 ·Cancer Research ·Paul Yenerall, Rahul K. Kollipara, (unknown), Michael Peyton, Christopher A. Eide, Daniel Bottomly, Shannon K. McWeeney, Yan Liu, Kenneth D. Westover, Brian Druker, John D. Minna, Ralf Kittler	6
7	NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells 2020 ·Signal Transduction and Targeted Therapy ·(unknown), (unknown), (unknown), Juan Luiz Coelho‐Silva, Renata Scopim‐Ribeiro, Priscila Santos Scheucher, Christopher A. Eide, Cristina E. Tognon, Brian Druker, Eduardo Magalhães Rego, João Agostinho Machado‐Neto, Fabı́ola Traina	24
8	Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia 2020 ·Leukemia ·Christopher A. Eide, Stephen E. Kurtz, Andy Kaempf, Nicola Long, Anupriya Agarwal, Cristina E. Tognon, Motomi Mori, Brian Druker, Bill H. Chang, Alexey V. Danilov, Jeffrey Tyner	16
9	Differentiation of leukemic blasts is not completely blocked in acute myeloid leukemia 2019 ·Proceedings of the National Academy of Sciences ·Anupriya Agarwal, William J. Bolosky, David B. Wilson, Christopher A. Eide, Susan B. Olson, Guang Fan, Brian Druker	17
10	Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation 2019 ·Cancer Research ·George M. Burslem, Anna Reister Schultz, Daniel P. Bondeson, Christopher A. Eide, Samantha L. Savage, Brian Druker, Craig M. Crews	165
11	Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia 2019 ·Leukemia ·Susan Branford, Dennis Dong Hwan Kim, Jane F. Apperley, Christopher A. Eide, Satu Mustjoki, S. Tiong Ong, Georgios Nteliopoulos, Thomas Ernst, Charles Chuah, Carlo Gambacorti‐Passerini, Michael J. Mauro, Brian Druker, Dong‐Wook Kim, François‐Xavier Mahon, Jörge E. Cortes, Jerry Radich, Andreas Hochhaus, Timothy P. Hughes	84
12	Biomarkers Predicting Venetoclax Sensitivity and Strategies for Venetoclax Combination Treatment 2018 ·Blood ·Haijiao Zhang, Beth Wilmot, Daniel Bottomly, Stephen E. Kurtz, Christopher A. Eide, Alisa Damnernsawad, Kyle A. Romine, Shyam A. Patel, Brian Druker, (unknown), Ravindra Majeti, Jeffrey Tyner	23
13	Therapeutically Targetable ALK Mutations in Leukemia 2015 ·Cancer Research ·Julia E. Maxson, Monika A. Davare, Samuel B. Luty, Christopher A. Eide, Bill H. Chang, Marc Loriaux, Cristina E. Tognon, Daniel Bottomly, Beth Wilmot, Shannon K. McWeeney, Brian Druker, Jeffrey Tyner	17
14	The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I 2015 ·Clinical Cancer Research ·Julia E. Maxson, Samuel B. Luty, Jason D. MacManiman, Jason C. Paik, Jason Gotlib, Peter L. Greenberg, (unknown), Samantha L. Savage, Melissa L. Abel, Christopher A. Eide, Marc Loriaux, Emily A. Stevens, Jeffrey Tyner	37
15	A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1 -Rearranged Lung Cancer 2015 ·Clinical Cancer Research ·Alexander Drilon, Romel Somwar, Jacob P. Wagner, Nadeem A. Vellore, Christopher A. Eide, Matthew S. Zabriskie, Maria E. Arcila, Jaclyn F. Hechtman, Lu Wang, Roger S. Smith, Mark G. Kris, Gregory J. Riely, Brian Druker, Thomas O’Hare, Marc Ladanyi, Monika A. Davare	128
16	Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia 2014 ·Clinical Cancer Research ·Anupriya Agarwal, (unknown), Raffaella Pippa, Christopher A. Eide, Jessica Oddo, Jeffrey Tyner, Rosalie C. Sears, Michael P. Vitek, María D. Odero, Dale J. Christensen, Brian Druker	103
17	Threshold Levels of ABL Tyrosine Kinase Inhibitors Retained in Chronic Myeloid Leukemia Cells Determine Their Commitment to Apoptosis 2013 ·Cancer Research ·Thomas O’Hare, Christopher A. Eide, Anupriya Agarwal, Lauren T. Adrian, Matthew S. Zabriskie, (unknown), Dorian LaTocha, Kara Johnson, Huihong You, (unknown), Steven M. Riddle, Bryan D. Marks, Kurt W. Vogel, Dennis R. Koop, John Apgar, Jeffrey Tyner, Michael W. Deininger, Brian Druker	23
18	KIT Signaling Governs Differential Sensitivity of Mature and Primitive CML Progenitors to Tyrosine Kinase Inhibitors 2013 ·Cancer Research ·Amie S. Corbin, Thomas O’Hare, Zhimin Gu, Ira L. Kraft, Anna M. Eiring, Jamshid S. Khorashad, Anthony D. Pomicter, Tian Yi Zhang, Christopher A. Eide, Paul W. Manley, Jörge E. Cortes, Brian Druker, Michael W. Deininger	17
19	The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile 2011 ·Cancer Research ·Christopher A. Eide, Lauren T. Adrian, Jeffrey Tyner, (unknown), David J. Anderson, Scott Wise, Bryan D. Smith, Peter A. Petillo, Daniel L. Flynn, Michael W. Deininger, Thomas O’Hare, Brian Druker	77
20	Activation switch pocket inhibitors target the T315I mutant of BCR-ABL 2008 ·Cancer Research ·Thomas O’Hare, Christopher A. Eide, Scott Wise, Bryan D. Smith, Peter A. Petillo, Daniel L. Flynn, Brian Druker	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact